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Despite recommendations of three Human Papillomavirus (HPV) vaccine shots 
for all adolescent girls, only 29.1% of non-Hispanic Whites and 23.4% of Hispanics 
achieve completion. This study describes factors associated with completion of the HPV 
vaccine series among Hispanic and non-Hispanic White 13-17 year old girls who initiated 
the series. A secondary data analysis was performed of the cross-sectional 2009 National 
Immunization Survey–Teen survey. Despite similar initiation rates (one in five), Hispanic 
girls who had initiated the series (59.9%) were less likely to complete the series than non-
Hispanic Whites (76.4%). After accounting for poverty status and home ownership, 
Hispanics were less likely to complete the HPV vaccine series. Factors associated with 
HPV vaccine series initiation were age at interview and age at HPV vaccine series 
initiation for Hispanics; and continuous health insurance since age of 11, mother’s marital 







FACTORS ASSOCIATED WITH COMPLETION OF THE HUMAN 
PAPILLOMAVIRUS VACCINE SERIES AMONG HISPANIC AND NON-






Maria Teresa Demarco 
 
 
Thesis submitted to the Faculty of the Graduate School of the 
University of Maryland, College Park, in partial fulfillment 
of the requirements for the degree of 









Professor Olivia Carter-Pokras, Chair 
Professor Xin He 
















Table of Contents 
 
List of Tables      iii 
List of Figures      iv 
Glossary of terms     v 
Chapter I: Introduction    1 
Background     1 
Public Health Significance   9 
Research Question/Specific Aims  10 
Chapter II: Methods     11 
 Study design     11 
 Study  population    12  
 Human subjects    13 
 Measurements     14 
 Statistical analysis    16 
Chapter III: Results     18 
Chapter IV: Discussion    22 
 Strengths     25 
 Limitations     26 
 Future studies     28 
 Conclusion     28 
Tables       29 
Figures      40 
References      41 
iii 
 
List of Tables 
 
 
Table 1:   Factors associated with initiation and completion of HPV vaccine series 
based on previous literature 
 
Table 2:  Sociodemographic characteristics of all Hispanic and non-Hispanic White 
girls ages 13 to 17 with adequate provider data, weighted, with sample 
design 
 
Table 3:  Rates of initiation of the HPV vaccine series among all Hispanic and non-
Hispanic White girls ages 13 to 17 with adequate provider data, weighted, 
with sample design 
 
Table 4:  Sociodemographic characteristics of Hispanic and non-Hispanic White 
girls ages 13 to 17 who have initiated the series at least a year prior to 
interview  and who have adequate provider data, weighted, with sample 
design 
 
Table 5:  Distribution of factors affecting completion of the 3-dose HPV vaccine 
series among Hispanic and non-Hispanic White girls ages 13 to 17 who 
have initiated the series at least a year prior to interview and who have 
adequate provider data, weighted, with sample design 
 
Table 6:  Rates of completion of the 3-dose HPV vaccine series among Hispanic 
and non-Hispanic White girls ages 13 to 17 who have initiated the series at 
least a year prior to interview and who have adequate provider data, 
weighted, with sample design 
 
Table 7:  Predictors of completion of the 3-dose HPV vaccine series among 
Hispanic and non-Hispanic White girls ages 13 to 17 who have initiated 
the series at least a year prior to interview and who have adequate provider 
data, weighted, with sample design 
 
Table 8:  Predictors of completion of the 3-dose HPV vaccine series among 
Hispanic girls ages 13 to 17 who have initiated the series at least a year 
prior to interview and who have adequate provider data, weighted, with 
sample design 
 
Table 9:  Predictors of completion of the 3-dose HPV vaccine series among non-
Hispanic White girls ages 13 to 17 who have initiated the series at least a 
year prior to interview and who have adequate provider data, weighted, 






List of Figures 
 
 
Figure 1:  Factors potentially associated with completion of the Human 




Glossary of terms 
 
 
ACIP  Advisory Committee on Immunization Practices 
AHRQ Agency for Healthcare Research and Quality 
CDC  Centers for Disease Control and Prevention 
HepB  Hepatitis B 
HPV  Human Papillomavirus 
IRB  Institutional Review Board 
LEP  Limited English language proficiency 
MenACWY Meningococcal conjugate 
MMR  Measles, mumps, rubella 
MPH  Master of Public Health 
NHIS  National Health Interview Survey 
NCHS  National Center for Health Statistics 
NCI  National Cancer Institute 
NCIRD National Center for Immunization and Respiratory Diseases 
NIS-Teen National Immunization Survey – Teen 
SCHIP State Children’s Health Insurance Program 
SES  Socio-economic status 
SGO  Society of Gynecologic Oncologists 
Tdap  Tetanus, diphtheria, acellular pertussis 
UMCP University of Maryland College Park 
VAR  Varicella 
VFC  Vaccine for Children 
VLP  Virus-like particles 




Chapter I: Introduction 
Background 
 Human Papillomavirus (HPV) is the most common sexually transmitted infection 
in the United States, (CDC, 2007). It affects 6.2 million persons 15 to 44 years of age 
annually, and an overall high-risk HPV prevalence of 23% was reported in 2003-2005, 
(CDC, 2007; Datta, et al., 2008). Prevalence varies by age group:  35% in persons 14 to 
19 years of age, 29% in those 20 to 29, 13% in those 30 to 39, 11% in those 40 to 49, 
and 6.3% in those 50 to 65, (Datta, et al., 2008). Since the majority of HPV infections 
are asymptomatic and most infected individuals are unaware of their infection, 
transmission occurs frequently without knowledge of either partner, (Giuliano, 2007). 
HPV types 6 and 11 account for 90% of genital warts, and types 16 and 18 are 
responsible for 70% of cervical cancer in women, (CDC, 2007). HPV is associated with 
cervical cancer and less common anogenital cancers such as cancer of the vulva, vagina, 
penis, and anus, (CDC, 2007).
 
 Given the established causal association between HPV 
and cervical cancer, prophylactic HPV vaccination represents a potential means of 
lowering the chances of both cervical cancer and precursor lesions, (Stanley, 2007).  
While implementation of cytologic screening programs with Pap screening has 
achieved dramatic decreases in both incidence and mortality from cervical cancer, in the 
U.S. 12,200 women were diagnosed with cervical cancer, and 4,210 women died from 
the disease in 2010, (NCI, 2010). Since HPV is a requisite for the development of 
invasive cervical cancer, strategies involving HPV testing have been incorporated into 
primary screening programs to allow for the detection and subsequent eradication of 
pre-invasive cervical dysplasia, (SGO, 2006). 
2 
 
Substantial racial, ethnic, and socioeconomic disparities exist for HPV infection, 
cervical cancer incidence, cervical cancer mortality, stages of diagnosis, and five-year 
survival rates, (Downs, Smith, Scarinci, Flowers, & Parbam, 2008). Cervical cancer 
incidence rates per 100,000 people in the U.S. are 7.5 for non-Hispanic Whites, 10.2 for 
non-Hispanic Blacks and 11.5 for Hispanics, (U.S. Cancer Statistics Working Group, 
2010). Similarly, cervical cancer mortality rates per 100,000 people in the U.S. are 2.2 
for non-Hispanic Whites, 4.3 for non-Hispanic Blacks, and 4.0 for Hispanics, (U.S. 
Cancer Statistics Working Group, 2010). 
The main public health goals of developing an HPV vaccine are to reduce the 
incidence of cervical cancer and its precursor lesions, and to reduce the incidence of 
other HPV associated cancers and the benign conditions caused by HPV, (SGO, 2006). 
Two prophylactic vaccines, a bivalent (HPV-16 and HPV-18) vaccine and a 
quadrivalent (HPV-16, -11, -6, -18) vaccine have been developed, (Rambout, 2007). In 
June 2006, the U.S. Food and Drug Administration (FDA) approved Merck’s Gardasil, a 
quadrivalent HPV vaccine containing virus-like particles of types 6,11,16,18, (CDC, 
2007).
1
 Clinical trials of the quadrivalent HPV vaccine have demonstrated 90%-100% 
efficacy in preventing precancerous cervical lesions attributable to HPV-16 and HPV-
18 and anogenital disease caused by HPV-6 and HPV-11 among women who were 
uninfected before vaccination and who received all three vaccine doses, (Rambout, 
2007; Fernandez, Allen, Mistry, & Kahn, 2010).  
                                                             
1 The bivalent Cervarix vaccine by GalaxoSmithKline was approved by FDA in October 2009 (FDA, 2009). 
Since data collection for this study occurred between January 2009 and May 2010 it is less likely that 
females in this sample received the bivalent vaccine than the quadrivalent. 
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The Centers for Disease Control and Prevention (CDC) in the United States and 
the World Health Organization (WHO) Global Advisory Committee on Vaccine Safety 
have concluded that clinical trials data support the safety and efficacy of HPV vaccines, 
(CDC, 2007; WHO, 2006). Since efficacy is substantially lower among women who may 
be HPV-infected at the time of vaccination, the HPV vaccine had the most significant 
impact if vaccination is targeted to young adolescents, prior to sexual initiation and thus 
before HPV acquisition, (Paavonen, Jenkins, Bosch, Naud, & Salmeron, 2007).  
In 2007, the Advisory Committee on Immunization Practices (ACIP) 
recommended that three doses of quadrivalent HPV vaccination (administered at 0, 2 and 
6 months) be targeted to girls ages 11 or 12 years, with catch-up immunization  
recommended for ages 13-26, (CDC, 2007). In the case of boys, the ACIP has 
recommended against the routine use of HPV vaccine but leaves decisions on whether to 
immunize males ages 9-26 up to their health care professionals, (CDC, 2007). 
Since ACIP recommendations for HPV vaccination were published, many policy 
and regulatory activities have been implemented to promote uptake of the vaccine among 
girls. These activities have focused on: financing HPV vaccination (particularly though 
the Vaccine for Children (VFC) program, Medicaid, and private insurance), mandating 
HPV vaccination for school age girls, and educating about HPV vaccination, (Fernandez, 
Allen, Mistry, & Kahn, 2010). 
Despite the ACIP’s recommendations and the government’s support in making 
HPV vaccine series available, the reported rates of HPV vaccination remain low. In 2008, 
44.3% of adolescent females (aged 13–17) had initiated the HPV vaccine series, and only 
26.7% of the adolescent females had completed the series, (CDC, 2009). Great variability 
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in initiation of the HPV vaccine series was observed throughout the different states, 
ranging from 30.2% in Idaho to 69.0% in Massachusetts, (CDC, 2009). There were 
significant differences in initiation of the series among those above poverty level (51.9%) 
and those at or below poverty level (42.5%), but no statistically significant differences in 
initiation were observed for racial/ethnic minorities, (CDC, 2009). However, significant 
disparities exist in completion of the series: (29.1% of non-Hispanic Whites, 23.4% of 
Hispanics, and 23.1% of non-Hispanic Blacks complete the series), (CDC, 2009).  
Despite similar completion rates between Hispanics and non-Hispanic Blacks, this 
study focused on examining factors associated with completion of the HPV vaccine series 
among adolescent Hispanics and non-Hispanic Whites who initiated the series. 
According to the Agency for Healthcare Research and Quality (AHRQ), Latinos are 
particularly at risk because they are less likely to have health insurance, less likely to 
have a usual source of care, less likely to be health literate, and more likely to have poor 
patient-provider communication in comparison to non-Hispanic Whites and non-Hispanic 
Blacks, (AHRQ, 2009).  
While many studies have documented factors affecting initiation of the series, 
very few studies have examined correlates for completion of the HPV vaccination series 
among 9-26 year old girls and young women who initiated the series. Table 1 
summarizes key factors associated with initiation and completion of HPV vaccine series 
based on previous literature, (Conroy, et al., 2009; Cook, et al., 2010; Jain, Euler, Shefer, 
Lu, Yankey, & Markowitz, 2009; Baker, Dang, Ly, & Diaz, 2010; Brewer & Fazekas, 
2007). Access to health care services and socio-economic status (SES) were positively 
correlated with both initiation and completion of the series. Race/ethnicity also plays a 
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role for completion of the series, with non-Hispanic Whites being more likely to achieve 
completion.  
Studies addressing characteristics that play a role in HPV vaccine series 
completion have focused on socio-demographic variables to identify some of the barriers 
in achieving higher vaccination rates among adolescents who initiated the series, (Chao, 
Velicer, Slezak, & Jacobsen, 2009; Dempsey, Cohn, Dalton, & Ruffin, 2010; Neubrand 
TP, 2009; Tan, Viera, Rowe-West, Grimshaw, Quinn, & Walter, 2011). Being an ethnic 
minority, living in areas with lower neighborhood educational level, and living far from a 
metropolitan statistical area were associated with poor HPV vaccine completion among 
girls who had initiated the series, (Chao, Velicer, Slezak, & Jacobsen, 2009; Tan, Viera, 
Rowe-West, Grimshaw, Quinn, & Walter, 2011). Health insurance coverage was found to 
be the strongest predictor of series completion among those who had received the first 
shot. Girls with private health insurance had the highest rates of completion among those 
who initiated the series, and girls with public health insurance were twice as likely to 
complete the series compared to girls without health insurance, (Widdice, Bernstein, 
Leonard, Marsolo, & Kahn, 2011). While the number of previous primary care provider 
visits was positively associated with completion of the series among those who initiated 
it, the number of prior hospitalizations and emergency department visits were negatively 
associated with completion, (Chao, Velicer, Slezak, & Jacobsen, 2009). While series 
initiation was more common at preventive care visits, series completion was most 
common at immunization-only visits, (Dempsey, Cohn, Dalton, & Ruffin, 2010). 
Factors affecting compliance with medical treatment in the general population 
include side effects, fear of future risk of the disease, cost, negative health experience, 
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illness beliefs, and acceptability, (Elliott, Ross-Degnan, Adams, Safran, & Soumerai, 
2007). Infant vaccination compliance has been shown to be unusually high due to routine 
well-child visits, a good understanding of universally recommended vaccination 
schedules by pediatric medical providers, high parental awareness of the importance of 
vaccination, and external requirements such as school entry laws, (Nelson, et al., 2009). 
However, vaccination compliance among adolescents is hindered by additional barriers.  
Multiple factors contribute to difficulties immunizing adolescents. First, 
adolescents do not seek preventive health care, decreasing the likelihood that they will be 
immunized using new vaccines and that they will come back for multiple doses, (Society 
for Adolescent Medicine, 2006). Second, there is a general lack of awareness among 
parents and adolescents about the risk and severity of infectious diseases and the need for 
immunization, leading to a lack of prioritization of vaccination relative to other medical 
care, (Nelson, et al., 2009). Third, some studies reveal misconceptions among health care 
workers about new vaccines, resulting in suboptimal compliance, (Lehmann & Benson, 
2009). Fourth, parents are often misinformed about which vaccines their adolescents 
should receive and when due to the frequent updates and changes to the adolescent 
vaccine schedule, (Nelson, et al., 2009). Fifth, time constraints may play a role in 
compliance to multi-dose vaccines with rigid schedules, (Society for Adolescent 
Medicine, 2006). Finally, the cost of immunization is still an obstacle for immunization 
adherence, (Lehmann & Benson, 2009).  
ACIP recommends that the following vaccines are included in adolescent females 
immunization schedules: meningococcal conjugate (MenACWY, 1 dose); tetanus, 
diphtheria, acellular pertussis (Tdap, 1 dose); and for females human papillomavirus 
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(HPV, 3 doses), (CDC, 2009). Adolescents are also advised to receive any of the 
recommended childhood vaccinations they might have missed. These include: measles, 
mumps, rubella (MMR, 2 doses); hepatitis B (HepB, 3 doses); and varicella (VAR, 2 
doses), (CDC, 2010). Based on 2009 NIS-Teen data, while childhood immunization 
coverage is high (MMR: 89.1%, HepB: 89.9%; and VAR: 75.7%), vaccines targeted for 
adolescents show much lower coverage rates for the recommended doses (Tdap: 55.6%; 
MenACWY: 53.6%; and HPV: 26.7%), (CDC, 2009). The only recommended vaccine 
that showed a statistically significant difference in coverage between Hispanics and non-
Hispanic Whites was HPV vaccine (≥3 doses), (CDC, 2009).  
In the case of the HPV vaccine, additional barriers need to be overcome. Since 
HPV is a sexually transmitted disease, some parents may be uncomfortable with 
perceived implications of HPV vaccine administration. Some have cited religious 
concerns about sexual behavior and fears that immunization may lead to promiscuity, 
while others have mentioned feeling no need to immunize because they trusted their 
children, (Constantine & Jerman, 2007). Some physicians have also expressed 
reservations about discussing sexuality before vaccination and feel more comfortable 
administering the vaccine to older rather than younger adolescents, (Daley, Liddon, 
Crane, & al, 2006).   
High cost is a particularly important barrier to obtaining HPV vaccination and 
lack of health insurance coverage is a frequently cited barrier to delivery of adolescent 
immunization, (American Academy of Pediatric Comm Adolesc, 2009; Dempsey, Cohn, 
Dalton, & Ruffin, 2010; Downs, Smith, Scarinci, Flowers, & Parbam, 2008). The 
quadrivalent HPV vaccine is one of the most costly of all available pediatric and adult 
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vaccines, with an estimated cost of US$130 per dose (US$390 for three doses) for the 
private sector, and US$105 per dose for the public sector after CDC negotiations, (CDC, 
2007; Gerend, Lee, & Shepherd, 2007). In the United States, the cost of vaccination is 
covered for many girls with private insurance and is also covered for many low-income 
girls by public financing, (Medicaid and the VFC program), (Adams, Newacheck, Park, 
Brindis, & Irwin, 2007). However, not all private insurance plans cover the cost of 
vaccination and adolescents from low-income families may not qualify for public 
financing, (Adams, Newacheck, Park, Brindis, & Irwin, 2007). In addition to those gaps, 
private insurance coverage and coverage through federal and state programs only 
partially address the cost barrier, since they do not account for the costs associated with 
clinic visits and the time spent in obtaining the HPV vaccine, (Wooten, Luman, & 
Barker, 2007).  
Compliance with multidose adolescent-targeted vaccines like HPV requires a shift 
in parental expectations for the frequency of adolescent preventive health visits. While 
vaccine-related visits could potentially be used to augment adolescent preventive care 
services by providing additional opportunities for screening and counseling, there is 
concern that parents may find it difficult to bring their adolescent to the medical office so 
frequently, which could result in underutilization of vaccines, (Dempsey, Singer, Clark, 
& Davis, 2009).   
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Public Health significance 
HPV vaccination has been acknowledged as a priority by the U.S. Department of 
Health and Human Services through the inclusion of three objectives (IID-11.4, C-10, 
and STD-9) in the Healthy People 2020 agenda, (USDHHS, 2010). Under the topic of 
Immunization and Infectious disease, we find objective IID-11.4: 3 doses of Human 
Papillomavirus vaccine for females by age 13 to 15 years. The baseline for this objective 
is 17% of females aged 13 to 15 years reported being vaccinated with 3 doses of the HPV 
vaccine in 2008, according to NIS-Teen, (CDC, 2009). The target for this objective is 
80% of females 13-15 receiving 3 doses of the vaccine, in consistency with national 
programs. Related objectives include a 10% reduction of invasive uterine cervical cancer 
(C-10), and reduction of the proportion of females with HPV infections of types 6, 11, 
16, and 18 (STD-9). 
The few existing publications that analyze the correlates for HPV vaccine 
completion among teenage girls in the Unites States conclude that the rates of completion 
differ between non-Hispanic Whites and Hispanics but further research is needed to 
explore barriers to completion among Hispanics (CDC, 2009; Chao, Velicer, Slezak, & 
Jacobsen, 2009; Tan, Viera, Rowe-West, Grimshaw, Quinn, & Walter, 2011). While 
socio-demographic factors and access to health care services might play a role, the 
reasons underlying racial disparities in completion of the series are unclear. 
Disparities in rates of completion among Hispanics are particularly concerning 
given the higher incidence and mortality rates from cervical cancer in this population. A 
genuine public health concern in the United States is the possibility of exacerbating these 
racial disparities in cervical cancer by non-completion of the vaccine series.  
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Research Question/Specific Aims  
The overall goal of this study is to describe factors associated with completion of 
the HPV vaccine series among adolescents who initiated the series to better understand 
the impact of health care access and utilization as well as socio-demographic factors in 
continuity of care.  
This study aims to: 
1. Identify factors associated with completion of the HPV vaccine series among 
Hispanic and non-Hispanic White teens ages 13 to 17 who have received one dose of 
HPV vaccine. 
Descriptive statistics on selected variables provide information on the impact of 
race/ethnicity, SES, access and use of health care services, health insurance coverage, 
and geographic mobility on completion of the series. 
Our hypotheses were that the lowest rates of completion would occur among 
Hispanics, those with lower SES, those with more limited access and use of health 
care services, those who are uninsured, and those with more geographic mobility
2
.  
2. Examine variations by race/ethnicity in the factors associated with completion of the 
HPV vaccine series among teens ages 13 to 17 who have received one dose of HPV 
vaccine. 
Our hypothesis was that, when considering stratified models by race/ethnicity, the 
factors associated with completion of the series would be different for Hispanics and 
for non-Hispanic Whites.  
  
                                                             
2 Geographic mobility is defined as state of residence at birth different from current state of residence 
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Chapter II: Methods 
Study Design 
We conducted a cross-sectional study using a subset of data reported by the 2009 
National Immunization Survey – Teen (NIS-Teen), sponsored by the National Center for 
Immunization and Respiratory Diseases (NCIRD) and conducted jointly by NCIRD and 
the National Center for Health Statistics (NCHS), Centers for Disease Control and 
Prevention (CDC). This survey collects data from telephone interviews with randomly 
selected households in all 50 States, the District of Columbia, and selected areas for 
oversampling. Consent is obtained from the parents or guardians of eligible adolescents 
to contact their vaccination providers. Mail surveys are then sent to healthcare providers 
to collect immunization data that assures the accuracy and precision of the vaccination 
coverage estimates.   
The target population for the NIS-Teen is adolescents between the ages of 13 and 
17 years living in non-institutionalized households in the United States at the time of the 
interview. Data from the NIS-Teen are used to produce timely estimates of vaccination 
coverage rates for all teen vaccinations recommended by the Advisory Committee on 
Immunization Practices (ACIP). 
The 2009 NIS-Teen collected household data from January 6, 2009 to February 
10, 2010, and provider data from January 2009 to May 2010. A total sample of 3.3 
million telephone numbers yielded household interviews for 35,637 teens, 20,399 of 
whom had provider data adequate to determine whether the teen was up-to-date with 
respect to the recommended immunization schedule.  
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The overall response rate was 58.0% following the methodology of the Council of 
American Survey Research Organization (CASRO). This rate takes into account the 
resolution rate (82.7%), screening completion rate (85.0%) and interview completion rate 
(82.5%).   
 
Study population 
Given the purpose of this study to describe factors associated with completion of 
the HPV vaccine series among adolescents Hispanic and non-Hispanic White girls ages 
13 to 17 who initiated the series, we restricted analyses to 13 to 17 year old Hispanic and 
non-Hispanic White females who initiated the HPV vaccine series at least a year prior to 
interview, who had complete provider data and sampling weights. 
While NIS-Teen had data on immunization for both males and females, given that 
the HPV vaccine has only been recommended for females, NIS-Teen only asked about 
HPV vaccination to female participants.  
Since Hispanics and non-Hispanic Whites show similar initiation rates but 
significantly different completion rates for the HPV vaccine series in the literature, our 
analysis was restricted to Hispanics and non-Hispanic Whites only, excluding non-
Hispanic Black only and non-Hispanic other. Based on our focus to assess the differences 
in completion, only those participants who had initiated the HPV vaccine series at least a 
year prior to the interview date were included. Those participants who initiated the series 
less than a year prior to the interview were excluded based on the assumption that they 
might not have had enough time to complete the series. Participants who never initiated 
the series were also excluded. 
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Data on immunization were obtained directly from the providers’ immunization 
records due to the higher reliability of this source compared to self-report. Our sample 
was then restricted to subjects with adequate provider data (57.4% of all age-eligible 
teens with completed household interviews). Since we conducted a weighted analysis 
accounting for clustering to better estimate associations in the entire population, only 
participants with appropriate sampling weights were included in the sample. After all 
exclusion criteria were met, the subjects included in our sample were 3,292 girls (560 
Hispanics and 2,732 non-Hispanic Whites). 
 
Human subjects 
We completed the Biomedical Research Basic Course offered by the 
Collaborative Institutional Training Initiative in 2010. Study protocols were submitted for 
approval by the Institutional Review Board (IRB), University of Maryland College Park 
(UMCP) prior to data analysis. Since we used non-personally identifiable data collected 
by NIS-Teen and released for public use, our study was classified in the exempt category 
number 4 (research involving the collection or study of existing data, documents or 
records, if these sources are publicly available or if the information is recorded by the 
investigator in such a manner that subjects cannot be identified, directly or through 
identifiers linked to the subjects). No additional data were collected for this study. We 
certify that all applicable institutional and governmental regulations concerning the 
ethical use of human subjects have been followed during this research project.  
Prior to data collection, NIS-Teen interviewers introduced the telephone survey 
and obtained oral consent from the respondents, assuring confidentiality of the responses, 
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and informing them of the voluntary nature of the survey. Informed consent was obtained 
from the person in the household most knowledgeable about the eligible teen’s 
immunization history. Informed consent to contact the teen’s vaccination provider was 
obtained at the end of the interview.  
Information in the NIS-Teen was collected and processed under strict 
confidentiality and can be used only for research. Prior to public release, the contents of 
the public use data file went through review by the NCHS Disclosure Review Board to 




The outcome of interest is “Completion of the HPV vaccine series,” analyzed as a 
binary (yes/no) outcome. Completion of the series was defined as documentation of 3 
separate vaccine doses, and it was measured using provider-reported data in the 2009 
NIS-Teen. Information for this variable was obtained using the age in years of provider-
reported HPV shot #3. The total number of teens in this category made up the “yes” 
category for the variable of interest. The category “no” was reconstructed subtracting the 
total number of those with 3 shots from the total number of those with at least 1 shot. 
Provider-reported data reflect vaccinations given both before and after the Household 
interview date and are considered the gold standard for immunization records given the 






The main exposure variable was race/ethnicity, assessed through the variable 
labeled as “Race/ethnicity of teen with multi-race category”. This is a categorical variable 
with values: Hispanic and Non-Hispanic White
3
 only. All other races were excluded from 
the sample population for the purpose of this analysis.  
 
Potential confounders/ effect modifiers 
Figure 1 outlines the selected factors potentially associated with completion of the 
Human Papillomavirus vaccine series in this study.  
Socioeconomic status was assessed through three variables. First, “Poverty status” 
(categorized into: below poverty, above poverty ≤$75,000, and above poverty >$75,000), 
taking into account the number of people in the household. The second variable was 
“Home ownership” (categorized into: owned/ being bought, or rented/other arrangement). 
The third variable was “Mother’s education” (categorized into: <12 years, 12 years, >12 
years, and college graduate). 
Use/access to health care was assessed through three variables: “In the past 12 
months, has the teen seen a doctor or other health care professional?” (categorized into 
Yes and No); “Since age 11, has there been any time when the teen was not covered by 
any health insurance?” (categorized into Yes and No); and “Hepatitis B vaccine
4
 series 
completion determined from provider info” (categorized into Yes and No).  
                                                             
3
 “Non-Hispanic White” was the terminology used on NIS-Teen methods of data collection 
4
 Hepatitis B vaccination was included in this study based on similarities with the HPV vaccine: 3 dose 
schedule, used to prevent STI transmission, and relatively recent approval by FDA 
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Age was a potential confounder in this study given that 13 year old girls are less 
likely to have had the time to complete the HPV vaccine series than 17 year olds. Age at 
time of interview, labeled “Age”, was analyzed as a categorical variable with possible 
values 13, 14, 15, 16, and 17. “Age at first shot” was also included in the model, 
categorized into values ≤13, 14, 15, 16, and 17.  
Other socio-demographic variables of interest based on the literature were 
“Mother’s marital status” (categorized into: Single and Married, with single including 
never married, widowed, divorced, separated, deceased), and “Number of children under 
18 years of age in the household” (categorized into: 1, 2-3, ≥4), and “Geographic 
mobility status” defined as the state of residence at birth being different from current state 
of residence (categorized into Yes and No). 
 
Statistical analysis 
Descriptive statistics were calculated to provide a quantitative description of the 
study population in terms of race/ethnicity, SES, access/use of health care services, and 
other socio-demographic variables. Chi-square tests were performed to look for 
significant differences between those who have completed the HPV vaccine series and 
those who have not completed it.  
A series of logistic regression models examined the independent effects of 
race/ethnicity (exposure) on HPV vaccine series completion (outcome). The results of the 
logistic regressions were used to estimate the odds ratios. To assess the potential 
confounders of the association between race/ethnicity and HPV vaccine series 
completion, bivariate regressions were used and those who produced a change in the 
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association between exposure and outcome greater than 10% were considered 
confounders in this study and were included in the final multivariate models. Variables 
that had an inverse effect for Hispanics and for non-Hispanic Whites were considered 
effect modifiers.  
All p-values were considered significant at ≤ 0.05 and 95% confidence intervals 
were reported when appropriate. Provider-phase sampling weights of teens with adequate 
provider data were used to produce national estimates excluding the U.S. Virgin Islands. 
These weights take into account selection probability, non-response, and non-coverage. 
All analyses also accounted for the effect of clustering in complex sample designs. SAS 




Chapter III: Results 
 
In 2009, Hispanic 13 to 17 year old girls had similar overall initiation rates as 
non-Hispanic Whites (Table 2).  Compared to non-Hispanic Whites, Hispanic girls were 
less likely to have completed the HPV vaccine series, have a doctor visit in the past year, 
have continuous health insurance coverage since the age of 11 years; and were more 
likely to have completed the Hepatitis B vaccine series, live in households with 4 or more 
children, live below poverty level, have single mothers with lower educational levels, and 
be geographically mobile (born in a state different from their current residence). Initiation 
rates did not show statistically significant variations by any of the variables studied 
(Table 3). 
Further analyses were restricted to 13 to 17 year old Hispanic (n=560, 
N=737,175) and non-Hispanic White (n=2,732, N=2,411,593) girls who had initiated the 
series. Hispanic 13 to 17 years old girls who had initiated the series were less likely to 
have completed the HPV vaccine series than non-Hispanic White girls (Table 4). There 
were significant socio-demographic differences between Hispanic and non-Hispanic 
White girls in the study sample. Compared to non-Hispanic White girls, Hispanic 13 to 
17 year old girls who had initiated the HPV vaccine series were less likely to have had a 
doctor visit in the previous year, and more likely to have a single mother with lower 
educational levels, live in households with 4 or more children, live in poverty, and live in 
a rental home. 
While 76.4% of the non-Hispanic White girls who initiated the HPV vaccine 
series in this sample completed the HPV vaccine series, only 59.9% of Hispanic girls 
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who had initiated the series achieved completion (Table 4). Among Hispanics, having 
had a doctor visit in the previous year, being older, and having initiated the series at a 
younger age were significantly associated with completion of the series (Table 5). 
Among non-Hispanic Whites, the factors associated with HPV vaccine series completion 
were: having continuous health insurance coverage since the age of 11, having married 
mothers, having mothers with higher levels of education, living households with fewer 
children, and not living in a rental home. 
Rates of HPV series completion were different for Hispanics and non-Hispanic 
White girls ages 13 to 17 years who had initiated the series (Table 6).  Non-Hispanic 
White girls were more likely than Hispanic girls to have completed the series among 
those who did not have a doctor visit in the previous year, had a single mother with lower 
levels of education, lived in households with 4 or more children, lived below poverty 
level, and lived in rental homes. On the other hand, continuity of health insurance 
coverage since the age of 11 years and geographic mobility acted as effect modifiers, 
with Hispanics showing inverse trends as those among non-Hispanic Whites. Among 
those who had not had continuous health insurance coverage since the age of 11 years, 
Hispanics were more likely than non-Hispanic Whites to have completed the HPV 
vaccine series, but among those who had continuous health insurance coverage since the 
age of 11 years, non-Hispanic Whites were more likely to have completed the series. 
Similarly, geographic mobility was associated with higher rates of completion among 
Hispanics and lower rates of completion among non-Hispanic Whites. 
Out of all the factors included in this study, the ones associated with lower odds 
of completing the HPV vaccine series were: being Hispanic (reference group: being non-
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Hispanic White) [OR= 0.462, 95% CI: 0.321-0.664], having a single mother (reference 
group: having a married mother) [OR=0.518, 95% CI: 0.336-0.797], living in households 
with 4 or more children (reference group: living in a household with only one child) 
[OR= 0.362, 95% CI: 0.188-0.697], living below poverty level (reference group: living 
above poverty level  >$75,000) [OR=0.519, 95% CI: 0.348-0.774], and living in a rental 
home (reference group: living in an owned property) [OR=0.502, 95% CI: 0.348-0.729] 
(Table 7). The multivariate model included race/ethnicity, poverty status, and home 
ownership as potential confounders of the association between race/ethnicity (main 
exposure) and HPV vaccine series completion (outcome). After adjusting for 
confounders, only race/ethnicity was associated with series completion [AOR=0.540, 
95% CI: 0.371-0.785], while poverty status and home ownership were not statistically 
significant. 
Among Hispanics, the factors associated with series completion were: not having 
a doctor visits in the previous year (reference group: having a doctor visit in the previous 
year) [OR=0.470, 95% CI: 0.221-0.997], being 16 years old at the time of HPV vaccine 
series initiation (reference group: being 13 years old at the time of HPV vaccine series 
initiation) [OR=0.271, 95% CI: 0.092-0.800], being 16 years old at the time of the 
interview (reference group: being 17 years old at the time of the interview) [OR=3.491, 
95% CI: 1.761-6.921], and being 15 years old at the time of the interview (reference 
group: being 17 years old at the time of the interview) [OR=0.435, 95%CI: 0.226-0.837], 
(Table 8). After adjusting for all of these potential confounders, being 16 years of age at 
the time of interview [AOR=3.079, 95% CI: 1.536-6.170] and being 16 years of age at 
the time of HPV series initiation [AOR=0.324, 95% CI: 0.107-0.978] were associated 
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with completion of the series but doctors visits in the last year was not statistically 
significant. 
Among non-Hispanic Whites, the factors associated with series completion were: 
not having continuous health insurance coverage since the age of 11 years (reference 
group: having continuous health insurance coverage since the age of 11 years) 
[OR=0.223, 95% CI: 0.062-0.801], having a single mother (reference group: having a 
married mother) [OR=0.469, 95% CI: 0.254-0.865], living in a household with 4 or more 
children (reference group: living in a household with only one child) [OR=0.308, 95% 
CI: 0.116-0.817], and living in a rental home (reference group: living in an owned 
property) [OR=0.534, 95% CI: 0.343-0.830], (Table 9). After adjusting for all of these 
potential confounders, not having continuous health insurance coverage since the age of 
11 years [AOR=0.362, 95% CI: 0.160-0.820], living in households with 4 or more 
children [AOR=0.416, 95% CI: 0.235-0.736], and having a single mother [AOR=0.564, 
95% CI: 0.349-0.911] were associated with completion of the series but living in a rental 




Chapter IV: Discussion 
 
While Hispanic 13 to 17 year old girls had similar overall initiation rates as non-
Hispanic Whites (19.7% and 19.8% respectively), completion rates were significantly 
different.  Seventy six percent (76.4%) of non-Hispanic White girls who had initiated the 
HPV vaccine series completed the 3-shot schedule, compared to 59.9% of Hispanic girls.  
High initiation rates among Hispanics might be a result of targeted cervical cancer 
prevention programs for the Hispanic population, such as public awareness campaigns to 
promote the use of the HPV vaccine and support from community health centers. 
However, these programs might be focusing on reaching as many people as possible 
without keeping track of those already in the system. It is a challenge for massive 
campaigns that look for cost-effective and short-term solutions to also provide the 
guidance and support needed for continuity of health care services. The HPV vaccine 
series adds new challenges to the existing efforts to reduce health disparities due to the 
necessity of compliance to treatment and continuity of access to health care services 
throughout a strict 3-dose schedule. Completion rates could improve by incorporating a 
tracking system to existing outreach programs and securing the resources needed to 
follow-up each patient. 
In this analysis, race/ethnicity was a significant predictor of HPV vaccine series 
completion, with Hispanic girls being less likely to complete the series than non-Hispanic 
White girls. This association between race/ethnicity and completion of the series was 
confounded by poverty status and home ownership in our analyses. Among Hispanics, 
while doctor visits in the previous year, age of teen at the time of interview, and at the 
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time of first HPV shot were associated with completion of the series, none of the SES 
variables showed a statistically significant association with completion of the series. On 
the other hand, SES played a stronger role among non-Hispanic Whites with lack of 
continuous insurance, mother’s marital status, number of children in the household, and 
home ownership being statistically associated with series completion. 
Our results show that financial barriers do not appear to fully explain the lower 
HPV vaccine completion rates among Hispanics, suggesting that non-financial barriers 
might be a stronger determinant of disparities between Hispanics and non-Hispanic 
Whites for HPV series completion. As Zambrana and Carter-Pokras have noted, “barriers 
to healthcare services among Hispanics can be financial, cultural, or structural,” 
(Zambrana & Carter-Pokras, 2004). 
Culture and language can add challenges to the use of health care services among 
Hispanics, (Flores, et al., 2002). Zambrana and Carter-Pokras (2004) further clarify that: 
“Limited English language proficiency (LEP), often times accompanied with lower 
educational or literacy levels, can drastically deteriorate the quality of health care 
services received by Hispanics”. It is necessary to address cultural and linguistic 
differences in clinical settings to reduce the disparities in access and use of health care 
services among Hispanics to achieve better clinical outcomes and overall health in this 
population, (Flores, et al., 2002). In order to achieve full understanding of the efficiency 
of HPV vaccination as a complete series and the importance of compliance among 
Hispanic girls, initiatives should be promoted at the policy level to support cultural and 
linguistic competency training among health care professionals.  
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While there have been federal and state attempts to protect the rights of LEP 
patients, medical institutions are not supportive of these initiatives due to increases in 
costs they are not willing to approve, (Flores, et al., 2002). It is important to address the 
problems faced by LEP Hispanics trying to interpret medical procedure and 
recommendations by developing measures to improve language access and patient 
compliance, (Zambrana & Carter-Pokras, 2004). Many programs  have taken place to 
reduce the cost of the HPV vaccine and similar negotiations or subsidies can help finance 
the care for LEP patients by reimbursing medical centers for medical interpreter services. 
Structural barriers such as “place of residence, lack of a regular source of care, 
distribution of healthcare resources, lack of outreach to potential beneficiaries, 
transportation problems, and excessive waiting times in clinics” are important factors in 
the lower quality and frequency of health care services received by Hispanics, (Zambrana 
& Carter-Pokras, 2004). Given these limitations, outreach programs can be implemented 
to capture the most vulnerable fragments of the Hispanic population. The HPV vaccine 
series imposes the burden of a 3-dose strict schedule within a 6 month period. This 
represents a significant difficulty for parents who might live far from the vaccination 
center, might not have the financial means to pay for transportation, might not have the 
opportunity to take time off of work to take their children to vaccination center, and 
might not have the flexibility in their schedule to accommodate the 3 doses on time. To 
lessen this burden, efforts should be made to incorporate a variety of health services in 
the same schedule. Additionally, research on effective HPV immunization through lower 





This study has major strengths such as the quality of the data gathered by NIS-
Teen. This database strengthened the present study in three ways: 
First, 2009 NIS-Teen offers the most up to date immunization data available. 
Three national surveys provide information on HPV vaccine usage. While the National 
Health Interview Service (NHIS) has immunization records from 2008 and the National 
Survey of Children’s Health (NSCH) has records from 2007, NIS-Teen has annual 
surveys and has already released its data for 2009.  
Second, 2009 NIS-Teen has an unusually large sample of teens vaccinated against 
HPV, allowing the analysis of a wide variety of variables. NHIS had a sample of 381 
girls vaccinated against HPV, and NSCH had a sample of 3,339 girls. The 2009 NIS-
Teen gives us information on 4,746 teens who initiated the HPV vaccine series, and 
3,010 who completed it, allowing for a more thorough analysis of factors affecting 
completion.  
The third advantage of the dataset used is that it offers provider reported data, 
improving the accuracy of the reports on immunizations. Out of the three sources for 
national data on HPV vaccine uptake, NIS-Teen is the only one that verifies their data 
through provider reports on immunization records instead of relying on the parents self-
report.  
The fourth strength of this study is that it is nationally representative and all 
analyses reported weights and adjustments for clustering. 
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Finally, this study includes variables that have not been addressed by previous 
studies on completion of HPV vaccine series, such as having received Hepatitis B 
vaccination, mother’s marital status, and poverty status. 
 
Limitations 
This study has several limitations including its cross sectional design. The 
collection of data at only one point in time limits the ability to make causal inferences 
and, in this particular case, did not allow us to assess the independent variables at the 
time of vaccination or during the interval between initiation and completion of the series. 
The only information available was for the time of the interview and this may or not have 
represented the situation at the time of vaccination.  
The cross-sectional study design presents an extra challenge for this study given 
that the immunization data is based on medical records and we do not know if the doctors 
interviewed have information on the complete immunization schedules of the teens or if 
the records are split between more than one doctor. This is a particularly greater concern 
for those subjects who were geographically mobile.  
Additionally, NIS-Teen did not collect data on subgroups within Hispanics. These 
factors might limit the generalizability of our results, particularly given our interest in 
Hispanic populations.  
Another limitation is the lack of availability of certain variables of interest in the 
public dataset for NIS-Teen. Questions regarding place of birth of the teen, having a 
usual source of care, and not receiving medical treatment due to cost were included in the 
27 
 
original NIHS-Teen 2009 questionnaire but were not available in the public dataset and 
could not be included in this analysis.  
The NIS-Teen 2009 questionnaire did not include behavioral and qualitative 
variables that have been shown to play an impact on initiation of the series and could be 
relevant for an analysis of the barriers encountered by Hispanics trying to complete the 
series. Other variables that, based on previous literature, could have been useful in our 
analysis but were not available included: area of residence, number of emergency visits in 
the previous year, type of doctor visits, health status of the teen, language spoken at 
home, patient/provider concordance, co-payments for health insurance coverage, and 
other logistic barriers.  
Regarding HPV immunization the questionnaire did not specify which HPV 
vaccine the teens have received. While the probability of a child receiving the bivalent 
vaccine is low, given that it was FDA approved in October 2009, the possibility does 
exist. However, the dosage of the bivalent vaccine is identical to that of the quadrivalent 
vaccine approved in 2006.  
The last limitation of this study is that, when adjustments were made to the 
weighted data in an effort to account for the complex sample design, the statistical power 
decreased, leading to wider confidence intervals for the odds ratios calculated. This might 
have influenced our findings making some clinically important factors associated with 






Since our results suggest that financial barriers might not be the most important 
barrier in HPV vaccine completion among 13-17 year old Hispanic girls who initiated the 
series, a qualitative analysis of the reasons why this is the case could provide very 
meaningful information. Patients, parents, and health care providers could offer insightful 
perspectives on this disparity. In addition to qualitative analyses, future studies should 
include additional quantitative information on potential confounders in the association 
between race/ethnicity and HPV vaccine series completion as well as quantitative 
information for subgroups of Hispanics. For this purpose, more quantitative data should 
be gathered to represent a larger Hispanic population to increase the accuracy of further 
statistical analyses. Ongoing data collection on immunization should incorporate new 
variables that might help explain vaccination patterns, and should make efforts to include 
a larger sample of racial/ethnic minorities. 
 
Conclusion 
This study confirms previous findings that despite similar initiation rates, 
Hispanic adolescent girls ages 13 to 17 years have lower overall completion rates of the 
HPV vaccine series than non-Hispanic White girls. However, financial barriers might not 
be the main source of these disparities. To reduce these disparities in HPV vaccine 
completion rates, cultural, linguistic, and structural barriers need to be acknowledged and 
incorporated into the political agenda. Future qualitative and quantitative studies are 
necessary to achieve a better understanding of the non-financial barriers to completion of 
HPV vaccine series among Hispanics.  
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Table 1.  Factors associated with initiation and completion of HPV vaccine series based 





Race/Ethnicity* Being Hispanic was 
associated with higher 
initiation rates 
Being non-Hispanic White 
was associated with higher 
completion rates 
Health insurance enrollment* Being enrolled in a health 
insurance plan was 
associated with higher 
initiation rates 
Having private insurance 
showed highest rates of 
completion, followed by 
having public insurance, and 
being uninsured 
Primary care provider visit* Number of primary care 
visits was positively 
associated with initiation of 
the series 
Number of primary care 
visits was positively 
associated with completion 
of the series 
Ever received Hep B 
vaccination* 
Teens who had received 
Hepatitis B vaccination 
shots had higher initiation 
rates 
Not studied 
Emergency visit Not studied Number of emergency visits 
was negatively associated 
with completion of the series 
Type of visit Initiation of the series 
happened most often during 
preventive care visits 
Completion of the series 
happened most often during 
immunization-only visits 
Mother’s education*  Teens with mothers with 
education levels above high 
school had higher initiation 
rates 
Teens living in 
neighborhoods with higher 
area educational levels had 
higher completion rates 
Mother’s marital status* Teens with non-married 
mothers had higher initiation 
rates 
Not studied 
Poverty status* Living over 200% above the 
poverty index was 
associated with higher 
initiation rates 
Not studied 
Area of residence  Living in urban or large 
rural areas was associated 
with higher initiation rates 
than living in small rural 
areas 
Living in urban or large rural 
areas was associated with 
higher completion rates than 
living in small rural areas 
Age* 13-15 years was the group 
with highest initiation rates 
13-15 years was the group 
with highest completion 
rates 
* Incorporated in this study 
 
Sources: Baker, et al. 2010, Brewer and Fazekas 2007, Chao, et al. 2009, Conroy, et al. 2009, Cook, et al. 
2010, Dempsey, et al. 2010, Jain, et al. 2009, Neubrand 2009, Tan et al. 2011, Widdice, et al. 2011.  
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Table 2. Sociodemographic characteristics of all Hispanic and non-Hispanic White 
girls ages 13 to 17 with adequate provider data, weighted, with sample design 
 
Characteristics Hispanics (%) 
(n=2,401,   N=3,746,305) 
Non-Hispanic Whites (%) 
(n=13,780,   N=12,193,579) 
HPV vaccine series initiation 
   Initiated 







HPV vaccine series completion ** 
   Complete 







Doctor visits in the last 12 months *** 
   No 







 Hepatitis B vaccine series ** 
   Complete 







Any time uninsured since 11 *** 
   Yes 







Age in years * 
   13 
   14 
   15 
   16 
   17  














Age in years at time of first HPV shot 
   13 
   14 
   15 
   16 













Mother’s marital status *** 
   Married 







Number of children in the household *** 
   1 
   2-3 









Poverty status2 *** 
   Above poverty level >$75K 
   Above poverty level ≤$75K 









Home ownership *** 
   Owned/being bought 







Mother’s education *** 
   <12 years 
   12 years 
   >12 years 











Geographic mobility1 *** 
   Yes 










1 Geographic mobility is defined as state of residence at birth different from current state of residence 
2 Taking into account the number of people in the household   
 
NOTE: Comparing Hispanics with non-Hispanic Whites: * p<0.05, ** p<0.01, *** p<0.001  
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Table 3: Rates of initiation of the HPV vaccine series among all Hispanic and non-
Hispanic White girls ages 13 to 17 with adequate provider data, weighted, with sample 
design 
 
Characteristics Hispanics (%) 
(n=2,401,   N=3,746,305) 
Non-Hispanic Whites (%) 







Doctor visits in the last 12 months  
   No 







 Hepatitis B vaccine series 
   Complete 







Any time uninsured since 11 
   Yes 







Age in years 
   13 
   14 
   15 
   16 













Mother’s marital status 
   Married 







Number of children in the household 
   1 
   2-3 









Poverty status2  
   Above poverty level >$75K 
   Above poverty level ≤$75K 









Home ownership  
   Owned/being bought 







Mother’s education  
   <12 years 
   12 years 
   >12 years 











Geographic mobility1  
   Yes 








1 Geographic mobility is defined as state of residence at birth different from current state of residence 
2 Taking into account the number of people in the household 
 
NOTE: Comparing Hispanics with non-Hispanic Whites: * p<0.05, ** p<0.01, *** p<0.001  
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Table 4: Sociodemographic characteristics of Hispanic and non-Hispanic White girls ages 13 
to 17 who have initiated the series at least a year prior to interview  and who have adequate 
provider data, weighted, with sample design 
Characteristics Hispanics (%) 
(n=560,   N=737,175) 
Non-Hispanic Whites (%) 
(n=2,732,   N=2,411,593) 
HPV vaccine series *** 
   Complete 







Doctor visits in the last 12 months *** 
   No 







 Hepatitis B vaccine series 
   Complete 







Any time uninsured since 11 
   Yes 







Age in years 
   13 
   14 
   15 
   16 
   17   













Age in years at time of first HPV shot 
   ≤13 
   14 
   15 
   16 











Mother’s marital status *** 
   Married 







Number of children in the household * 
   1 
   2-3 









Poverty status2 *** 
   Above poverty level >$75K 
   Above poverty level ≤$75K 









Home ownership *** 
   Owned/being bought 







Mother’s education *** 
   <12 years 
   12 years 
   >12 years 












   Yes 







1 Geographic mobility is defined as state of residence at birth different from current state of residence 
2 Taking into account the number of people in the household 
NOTE: Comparing Hispanics with non-Hispanic Whites: * p<0.05, ** p<0.01, *** p<0.001  
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Table 5: Distribution of factors affecting completion of the 3-dose HPV vaccine series among Hispanic 
and non-Hispanic White girls ages 13 to 17 who have initiated the series at least a year prior to interview 
and who have adequate provider data, weighted, with sample design 
Characteristics Hispanics (%) 
(n=560,   N=737,175) 
Non-Hispanic Whites (%) 
(n=2,732,   N=2,411,593) 
 Complete 
N = 441,739 
(59.9%) 
Incomplete 
N = 295,436 
(40.1%) 
Complete 
N = 1,842,740 
(76.4%) 
Incomplete 
N = 568,853 
(23.6%) 
Doctor visits in the last 12 months  # 
   No 













Hepatitis B vaccine series 
   Complete 













Any time uninsured since 11 ^^ 
   Yes 













Age in years ## 
   13 
   14 
   15 
   16 

























Age in years at time of first HPV shot # 
   ≤13 
   14 
   15 





















Mother’s marital status ^^ 
   Married  













Number of children in the household ^^ 
   1 
   2-3 


















   Above poverty level >$75K 
   Above poverty level ≤$75K 

















Home ownership ^^ 
   Owned/being bought 













Mother’s education ^^ 
   <12 years 
   12 years 
   >12 years 






















   Yes 













1 Geographic mobility is defined as state of residence at birth different from current state of residence 
2 Taking into account the number of people in the household 
NOTE: Comparing Hispanics complete with Hispanics incomplete: # p<0.05, ## p<0.01, ### p<0.001 




Table 6: Rates of completion of the 3-dose HPV vaccine series among Hispanic and non-Hispanic White 
girls ages 13 to 17 who have initiated the series at least a year prior to interview and who have adequate 
provider data, weighted, with sample design 
Characteristics Hispanics (%) 
(n=560,   N=737,175) 
Non-Hispanic Whites (%) 







Doctor visits in the last 12 months*** 
   No 







Hepatitis B vaccine series 
   Complete 







Any time uninsured since 11 * 
   Yes 







Age in years*** 
   13 
   14 
   15 
   16 













Age in years at time of first HPV shot*** 
   ≤13 
   14 
   15 











Mother’s marital status *** 
   Married  







Number of children in the household *** 
   1 
   2-3 









Poverty status2 * 
   Above poverty level >$75K 
   Above poverty level ≤$75K 









Home ownership *** 
   Owned/being bought 







Mother’s education  
   <12 years 
   12 years 
   >12 years 











Geographic mobility1 *** 
  Yes 








1 Geographic mobility is defined as state of residence at birth different from current state of residence 
2 Taking into account the number of people in the household 
NOTE: Comparing Hispanics with non-Hispanic Whites: * p<0.05, ** p<0.01, *** p<0.001  
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Table 7: Predictors of completion of the 3-dose HPV vaccine series among Hispanic and non-
Hispanic White girls ages 13 to 17 who have initiated the series at least a year prior to interview 
and who have adequate provider data, weighted, with sample design 
 
 Unadjusted 














   Hispanic 









Doctor visits in the last 12 months 
   No 






Hepatitis B vaccine series  
   Incomplete 






Any time uninsured since 11 
   Yes 






Age in years 
   13 
   14 
   15 
   16 












Age in years at time of first HPV shot 
   16 
   15 
   14 












Mother’s marital status ■ 
   Single 






Number of children in the household ■ 
   ≥4 
   2-3 










Poverty status2 ■▲ 
   Below poverty level 
   Above poverty level ≤$75K 















Home ownership ■▲ 
   Rented 










   <12 years 
   12 years 
   >12 years 











   Yes 










1 Geographic mobility is defined as state of residence at birth different from current state of residence 
2 Taking into account the number of people in the household 
† Reference group 
■ Statistically significant before adjustment  
▲Confounder    





Table 8: Predictors of completion of the 3-dose HPV vaccine series among Hispanic girls ages 
13 to 17 who have initiated the series at least a year prior to interview and who have adequate 
provider data, weighted, with sample design 
 Unadjusted 













Doctor visits in the last 12 months ■▲ 
   No 









Hepatitis B vaccine series 
   Incomplete 






Any time uninsured since 11 
   Yes 






Age in years ■▲● 
   13 
   14 
   15 
   16 





















Age in years at time of first HPV shot ■▲● 
   16 
   15 
   14 













Mother’s marital status  
   Single 






Number of children in the household  
   ≥4 
   2-3 








Poverty status2  
   Below poverty level 
   Above poverty level ≤$75K 








Home ownership  
   Rented 







   <12 years 
   12 years 
   >12 years 











   Yes 






1 Geographic mobility is defined as state of residence at birth different from current state of residence 
2 Taking into account the number of people in the household 
† Reference group  
■ Statistically significant before adjustment  
▲Confounder    
● Statistically significant after adjustment 
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Table 9: Predictors of completion of the 3-dose HPV vaccine series among non-Hispanic 
White girls ages 13 to 17 who have initiated the series at least a year prior to interview and who 
have adequate provider data, weighted, with sample design 
 Unadjusted 













Doctor visits in the last 12 months 
   No 






Hepatitis B vaccine series 
   Incomplete 






Any time uninsured since 11 ■▲● 
   Yes 









Age in years 
   13 
   14 
   15 
   16 












Age in years at time of first HPV shot 
   16 
   15 
   14 












Mother’s marital status ■▲● 
   Single 









Number of children in the household ■▲● 
   ≥4 
   2-3 











Poverty status2  
   Below poverty level 
   Above poverty level ≤$75K 








Home ownership ■▲ 
   Rented 










   <12 years 
   12 years 
   >12 years 











   Yes 






1 Geographic mobility is defined as state of residence at birth different from current state of residence 
2 Taking into account the number of people in the household 
† Reference group 
■ Statistically significant before adjustment  
▲Confounder    




Figure 1. Factors potentially associated with completion of the Human Papillomavirus 
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